MA33917B1 - Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue - Google Patents

Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue

Info

Publication number
MA33917B1
MA33917B1 MA35055A MA35055A MA33917B1 MA 33917 B1 MA33917 B1 MA 33917B1 MA 35055 A MA35055 A MA 35055A MA 35055 A MA35055 A MA 35055A MA 33917 B1 MA33917 B1 MA 33917B1
Authority
MA
Morocco
Prior art keywords
cycle
carboxylic acid
acid derivatives
substituted oxazolopyrimidine
oxazolopyrimidine
Prior art date
Application number
MA35055A
Other languages
Arabic (ar)
English (en)
Inventor
Dieter Kadereit
Matthias Schaefer
Stephanie Hachtel
Axel Dietrich
Thomas Huebschle
Katrin Hiss
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33917B1 publication Critical patent/MA33917B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés d'oxazolopyrimidine de la formule (i) dans laquelle a, r1, r2, r3 et x sont définis comme indiqués dans les revendications. Les composés de la formule (i) conviennent par exemple pour la cicatrisation de plaies.
MA35055A 2010-01-14 2011-01-12 Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue MA33917B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305042 2010-01-14
PCT/EP2011/050301 WO2011086079A1 (fr) 2010-01-14 2011-01-12 Dérivés d'acide carboxylique comprenant un noyau d'oxazolopyrimidine à substitution en 2,5

Publications (1)

Publication Number Publication Date
MA33917B1 true MA33917B1 (fr) 2013-01-02

Family

ID=41800578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35055A MA33917B1 (fr) 2010-01-14 2011-01-12 Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue

Country Status (31)

Country Link
US (1) US8846692B2 (fr)
EP (1) EP2523962B1 (fr)
JP (1) JP5841067B2 (fr)
KR (1) KR101759128B1 (fr)
CN (1) CN102791717B (fr)
AR (1) AR079997A1 (fr)
AU (1) AU2011206615B2 (fr)
BR (1) BR112012017437B1 (fr)
CA (1) CA2784560C (fr)
CL (1) CL2012001972A1 (fr)
CO (1) CO6612239A2 (fr)
CY (1) CY1115055T1 (fr)
DK (1) DK2523962T3 (fr)
ES (1) ES2441954T3 (fr)
HR (1) HRP20140179T1 (fr)
IL (1) IL220720A (fr)
MA (1) MA33917B1 (fr)
MX (1) MX2012007834A (fr)
MY (1) MY156550A (fr)
NZ (1) NZ601113A (fr)
PH (1) PH12012501265A1 (fr)
PL (1) PL2523962T3 (fr)
PT (1) PT2523962E (fr)
RS (1) RS53254B (fr)
RU (1) RU2564018C2 (fr)
SG (1) SG182484A1 (fr)
SI (1) SI2523962T1 (fr)
TW (1) TWI510242B (fr)
UY (1) UY33179A (fr)
WO (1) WO2011086079A1 (fr)
ZA (1) ZA201204174B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
UY33177A (es) 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
EP2523963B1 (fr) * 2010-01-14 2014-08-27 Sanofi Dérivés de l'oxazolopyrimidine à substitution 2,5 en tant qu'agonistes du récepteur edg-1
RU2559896C2 (ru) * 2010-01-14 2015-08-20 Санофи Гетероциклические производные карбоновых кислот, имеющие 2,5-замещенное оксазолопиримидиновое кольцо
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
EP2862574A1 (fr) * 2013-10-15 2015-04-22 Sanofi Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë
CN118697873A (zh) * 2023-03-27 2024-09-27 四川大学华西医院 S1pr1偏向性激动剂在制备治疗炎症性肠病的药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
JPH01242587A (ja) * 1988-03-25 1989-09-27 Sankyo Co Ltd 縮環オキサゾロチエノピリミジン誘導体
AU2004234110A1 (en) 2003-04-25 2004-11-11 Rega Foundation Heterocyclic compounds for use in the treatment of viral infections
CA2523677A1 (fr) * 2003-04-30 2004-11-11 Novartis Ag Derives d'amino-propanol comme modulateurs de recepteur de sphingosine-1-phosphate
ATE537825T1 (de) * 2003-05-19 2012-01-15 Irm Llc Immunosuppressive verbindungen und zusammensetzungen
MXPA05012461A (es) * 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresores.
MX2008002540A (es) * 2005-08-23 2008-03-14 Irm Llc Compuestos inmunosupresores y composiciones.
EP2364976B1 (fr) * 2007-03-21 2014-10-08 EPIX Pharmaceuticals, Inc. Composés de modulation de récepteur S1P et utilisation associée
TW201000099A (en) * 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
US8735387B2 (en) * 2008-07-15 2014-05-27 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
UY33177A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
AR079982A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5,7- sustituido., composiciones farmaceuticas y procesos para prepararlos.
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
EP2523963B1 (fr) * 2010-01-14 2014-08-27 Sanofi Dérivés de l'oxazolopyrimidine à substitution 2,5 en tant qu'agonistes du récepteur edg-1
RU2559896C2 (ru) * 2010-01-14 2015-08-20 Санофи Гетероциклические производные карбоновых кислот, имеющие 2,5-замещенное оксазолопиримидиновое кольцо

Also Published As

Publication number Publication date
WO2011086079A1 (fr) 2011-07-21
PL2523962T3 (pl) 2014-05-30
AR079997A1 (es) 2012-03-07
RS53254B (sr) 2014-08-29
SG182484A1 (en) 2012-08-30
PH12012501265A1 (en) 2016-07-27
JP2013517241A (ja) 2013-05-16
PT2523962E (pt) 2014-02-06
EP2523962B1 (fr) 2013-11-27
UY33179A (es) 2011-08-31
TWI510242B (zh) 2015-12-01
KR20120101732A (ko) 2012-09-14
CN102791717A (zh) 2012-11-21
BR112012017437B1 (pt) 2022-03-03
DK2523962T3 (en) 2014-03-10
ES2441954T3 (es) 2014-02-07
NZ601113A (en) 2013-07-26
CO6612239A2 (es) 2013-02-01
MY156550A (en) 2016-02-26
US20130079358A1 (en) 2013-03-28
TW201134475A (en) 2011-10-16
RU2564018C2 (ru) 2015-09-27
HRP20140179T1 (hr) 2014-03-28
BR112012017437A2 (pt) 2021-03-02
RU2012134630A (ru) 2014-02-20
CN102791717B (zh) 2016-03-30
CA2784560A1 (fr) 2011-07-21
SI2523962T1 (sl) 2014-02-28
HK1178885A1 (en) 2013-09-19
IL220720A (en) 2015-02-26
AU2011206615A1 (en) 2012-08-02
CL2012001972A1 (es) 2012-10-19
MX2012007834A (es) 2012-07-30
US8846692B2 (en) 2014-09-30
CY1115055T1 (el) 2016-12-14
KR101759128B1 (ko) 2017-07-18
IL220720A0 (en) 2012-08-30
JP5841067B2 (ja) 2016-01-06
ZA201204174B (en) 2013-02-27
AU2011206615B2 (en) 2015-03-19
CA2784560C (fr) 2017-12-05
EP2523962A1 (fr) 2012-11-21

Similar Documents

Publication Publication Date Title
MA33917B1 (fr) Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
TN2013000353A1 (fr) Dérivés de fluoro-pyridinone utiles comme agents antibactériens
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA33492B1 (fr) Inhibiteurs de bace
EA201070422A1 (ru) Производные оксадиазола
MA34397B1 (fr) Dérivés d'acide napht-2-ylacétique dans le traitement du sida
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MX2012002641A (es) Inhibidores de cinasa janus (jak).
EA200802054A1 (ru) Ингибиторы фермента
EA201171211A1 (ru) Производные оксадиазола
EP2519512A4 (fr) La présente invention concerne le domaine des N1-acyl-5-fluoropyrimidinones et de leurs dérivés et sur l'utilisation de ses composés comme fongicides